Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cognition in Schizophrenia Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

NCT03943537
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
Interventions
Intranasal Insulin
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Adult Study Oxytocin - Behavioral

NCT02567032
View directory record Official record
Conditions
Schizophrenia, Oxytocin, Social Cognition, Psychotic Disorders
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia

NCT00560937
View directory record Official record
Conditions
Schizophrenia
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

Building Employment Skills Through Therapy for Veterans

NCT01992913
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
integrated Cognitive Behavioral Therapy, Usual Care, Computerized cognitive remediation (CCR)
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional

Treatment of Social Cognition in Schizophrenia Trial

NCT02246426
View directory record Official record
Conditions
Schizophrenia
Interventions
Computerized plasticity-based adaptive cognitive training, Commercially available computerized training
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation

NCT00628394
View directory record Official record
Conditions
Cognition in Schizophrenia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

NCT01488929
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms, Cognitive Dysfunction
Interventions
TC-5619, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Garden Grove, California • Glendale, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Sodium Oxybate in Schizophrenia With Insomnia

NCT00594256
View directory record Official record
Conditions
Schizophrenia, Insomnia Related to Schizophrenia (307.42)
Interventions
Sodium Oxybate
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 23, 2026, 10:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Brain Stimulation on Cognition, Oscillations and GABA Levels in Schizophrenia

NCT04267003
View directory record Official record
Conditions
Schizophrenia
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 47 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional

Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia

NCT00546403
View directory record Official record
Conditions
Schizophrenia
Interventions
Modafinil, Placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2009 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone

NCT01173874
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Remediation
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
16
States / cities
Granada Hills, California • Orange, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

NCT04846881
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 23, 2026, 10:03 AM EDT
Active, not recruiting Not applicable Interventional

Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)

NCT04143126
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Enhancement Therapy, Enriched Supportive Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

NCT02237235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
MMFS-202-302, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults

NCT01422902
View directory record Official record
Conditions
Schizophrenia
Interventions
Plasticity-based Cognitive Training, Non-plasticity-based Training
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Alcohol Dependence and Comorbid Bipolar Disorder

NCT01015586
View directory record Official record
Conditions
Alcohol Dependence, Bipolar Disorder, Depression, Mania, Psychosis
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

NCT01009060
View directory record Official record
Conditions
Schizophrenia
Interventions
GSK239512, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Garden Grove, California • Los Angeles, California • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional

Cognitive Training and Enhanced Supported Employment in Schizophrenia

NCT00339170
View directory record Official record
Conditions
Schizophrenia
Interventions
Computer-Based Cognitive Enhancement Training Program, Work Therapy Program
Behavioral
Lead sponsor
Yale University
Other
Eligibility
20 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

NCT00802919
View directory record Official record
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Varenicline, Placebo for varenicline
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

NCT01730768
View directory record Official record
Conditions
Schizophrenia
Interventions
AQW051, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Garden Grove, California • Glendale, California • National City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

NCT01003379
View directory record Official record
Conditions
Cognitive Dysfunction, Schizophrenia
Interventions
TC-5619, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
National City, California • Torrance, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Jul 23, 2026, 10:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence

NCT01037075
View directory record Official record
Conditions
Schizophrenia, Drug Abuse/Dependency
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Jul 23, 2026, 10:03 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation

NCT05112432
View directory record Official record
Conditions
Psychosis
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Duluth, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 23, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

NCT04822883
View directory record Official record
Conditions
Cognitive Impairment, Schizophrenia
Interventions
RL-007, RL-007 Matching Placebo
Drug
Lead sponsor
Recognify Life Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Jul 23, 2026, 10:03 AM EDT